Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Interest Expense : $-5.01 Mil (TTM As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Parnell Pharmaceuticals Holdings's interest expense for the six months ended in Dec. 2018 was $ -5.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2018 was $-5.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Parnell Pharmaceuticals Holdings's Operating Income for the six months ended in Dec. 2018 was $ 2.45 Mil. Parnell Pharmaceuticals Holdings's Interest Expense for the six months ended in Dec. 2018 was $ -5.01 Mil. Parnell Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Dec. 2018 was 0.49. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Parnell Pharmaceuticals Holdings Interest Expense Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Interest Expense Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Interest Expense

Get a 7-Day Free Trial

-6.80

-0.93

-2.81

-7.07

-5.01

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Interest Expense	Get a 7-Day Free Trial			-6.80	-0.93	-2.81	-7.07	-5.01

Parnell Pharmaceuticals Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Interest Expense for the trailing twelve months (TTM) ended in Dec. 2018 was $-5.01 Mil.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Parnell Pharmaceuticals Holdings's Interest Expense for the six months ended in Dec. 2018 was $-5.01 Mil. Its Operating Income for the six months ended in Dec. 2018 was $2.45 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2018 was $32.28 Mil.

Parnell Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Dec. 2018 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2018 )	/	Interest Expense (Q: Dec. 2018 )
	=	-1	*	2.451	/	-5.014
	=	0.49

The higher the ratio, the stronger the company's financial strength is.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.